Last updated on July 2018

Study to Compare the Efficacy of Pristinamycin (Pyostacine ) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia


Brief description of study

Primary Objective:

To evaluate the clinical efficacy of pristinamycin at a dose of 2g x 2/day for 2 days then 1g x 3/day for 5 to 7 days versus amoxicillin 1g x3 /day for 7 to 9 days, 5 to 9 days after the end of treatment.

Secondary Objectives:

To evaluate the clinical efficacy in a subpopulation bacteriologically documented at inclusion and according to procalcitonin level.

To evaluate the efficacy of treatments against pneumococcus. To evaluate the rate of relapse and mortality 302 days after treatment is started.

To document failures. To collect and follow up adverse events.

Detailed Study Description

The total study duration for each patient is 1 month with a treatment period of 7 to 9 days and a follow-up period of 21 to 23 days.

Clinical Study Identifier: NCT02332577

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 250013
Antony, France
5.38miles
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 250025
Clamart, France
8.77miles
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 250016
Paris, France
9.88miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.